Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus
Executive Summary
Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.
You may also be interested in...
Biosimilars Adoption In Europe, US: Some Wins, 'Incomplete' Policies
Industry chiefs and experts, including Sandoz' global head of biopharmaceuticals, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.
Biosimilars Adoption In Europe, US: Some Wins, 'Incomplete' Policies
Industry chieftains and experts, including Sandoz biopharma's global head, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.
Viatris Pipeline Progress Includes Eylea, Botox Biosimilars
In its first sales and earnings call, Viatris management updated investors on the development of some key complex generics and biosimilars.